Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Tesla Raises Cybertruck Prices by $5,000 in US 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Trump Buys SpaceX Shares After Record IPO 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Add as a preferred source on Google
MENLO PARK, Calif., April 20, 2018 -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) will hold its quarterly conference call to discuss its First Quarter 2018 Financial Results on Wednesday, May 2, 2018, at 4:30pm Eastern Time.
The call will be webcast and may be accessed at Pacific Biosciences’ website at: http://investor.pacificbiosciences.com/.
Date: May 2, 2018
Time: 4:30pm ET
Listen via Internet: http://investor.pacificbiosciences.com/
Toll-free: 888.366.7247
International: 707.287.9330
Conference ID: 2187939
Replay: http://investor.pacificbiosciences.com
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.
Contact: Pacific Biosciences
Trevin Rard
650.521.8450
[email protected]
